Professor Andrew Barbour is an academic general surgeon and translational researcher at The University of Queensland , specifically affiliated with the School of Medicine under the Faculty of Health, Medicine and Behavioural Sciences . He specializes in upper gastrointestinal, pancreatic, melanoma, and sarcoma surgery , with expertise in robotic and laparoscopic procedures for conditions like oesophageal cancer and soft tissue tumours. Doctor of Philosophy, The University of Queensland Faculty of Anaesthetists, Royal Australasian College of Surgeons His research integrates genomic, epigenomic, and transcriptomic data to advance precision medicine in cancer , focusing on biomarker discovery for therapy response and recurrence prediction. Key contributions include the DOCTOR trial (first PET-guided personalized therapy for oesophageal cancer) and the GAP Trial (establishing preoperative chemotherapy for pancreatic cancer). Recent publications emphasize spatial transcriptomics for thin melanoma mortality prediction, multi-omic profiling of oesophageal adenocarcinoma, and radiomics for immune signature analysis in melanoma. His work also explores small extracellular vesicle heterogeneity and genomic catastrophes as drivers in cancer. Queensland Advancing Clinical Research Fellowship for melanoma recurrence prediction Key roles in NHMRC-funded trials and MRFF MASTERPLAN trial As Chair of the AGITG Upper GI working party , he leads national cancer research initiatives. His Surgical Oncology Lab at TRI operates the Cancer Evolution Biobank , linking tumour biology with clinical outcomes.










